MOGA Supports Medical Research Future Fund PPHRI – 2024 Survivorship Care and Collaborative Research Prioritisation Grant Opportunity
Medical Oncology Group of Australia (MOGA) is delighted to be a partner with The University of Sydney in the Medical Research Future Fund PPHRI – 2024 Survivorship Care and Collaborative Research Prioritisation Grant Opportunity for the program of work entitled: Transforming colorectal cancer survivorship with telehealth delivery of a multidisciplinary survivorship clinic, which is being led by University of Sydney’s Professor Janette Vardy.
About Medical Oncology Group of Australia (MOGA)
MOGA, the national professional organisation for Australian Medical oncologists and a specialty society of the Royal College of Physicians, represents Medical Oncology specialists at the national level. We contribute to the training of Medical Oncologists in Australia and advocate for improved access, affordability, and equity of cancer services.
The program of work proposed here aligns with MOGA’s commitment to ensuring equity of access to cancer care for all Australians affected by cancer, particularly priority populations such as regional, rural and remote patients and those from culturally diverse backgrounds. The program directly relates to MOGA’s priorities for enhanced cancer care into survivorship to improve outcomes of people diagnosed with cancer.
About the Proposal
The proposed project plan vision is to provide high quality evidence regarding improving the quality of care for survivors of colorectal cancer. This is timely, critical, and transformative for Australia's future health needs.
Overview of Medical Oncology Group of Australia’s participation in the proposal
MOGA will work with The University of Sydney and any other project partners to successfully complete the program of work, including but not limited to:
involvement in promotion of the project
If the study is positive, engage in advocacy for policy change to ensure the ongoing sustainability of this approach through the provision of appropriate reimbursement within the Australian healthcare system.
Our commitment to this program of work is demonstrated by:
As a partner to this exciting application, we endorse the project plan and are excited about the opportunity to be a part of the vision to deliver better quality and more patient centred and accessible multidisciplinary survivorship care to colorectal cancer patients.